One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs - Takeaways - MDSpire

One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs

  • By

  • Zhan-kui Du

  • Ya-song Wang

  • Ting-hao Zhao

  • Hou-lin He

  • Zhi-qiang Zhang

  • Xiao-zeng Wang

  • May 26, 2026

  • 0 min

Share

  • 1

    The study investigated 12-month outcomes and 6-month morphological changes in acute penetrating aortic ulcers after TEVAR with antiplatelet therapy.

  • 2

    A total of 195 patients underwent TEVAR for acute PAUs, with 59 receiving antiplatelet therapy and 136 not receiving it.

  • 3

    At 12 months, 15.8% of patients experienced major adverse events, with a higher cumulative incidence in the antiplatelet group, though not statistically significant.

  • 4

    Cox regression analysis identified maximum aortic diameter, PAU diameter ≥ 10.5 mm, and PAU depth ≥ 7.5 mm as factors associated with major adverse events.

  • 5

    Both groups showed significant reductions in PAU diameter, depth, and intramural hematoma thickness at 6 months, with no significant differences between them.

Original Source(s)

One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs

  • by Zhan-kui Du, Ya-song Wang, Ting-hao Zhao, Hou-lin He, Zhi-qiang Zhang, Xiao-zeng Wang

  • May 26, 2026

Related Content

May-Thurner Syndrome as a Hidden Etiology of Ischemic Stroke in Young Adults

Impact of frailty on post-procedural adverse outcomes in older adults aged ≥75 years undergoing percutaneous coronary intervention: a systematic review of observational studies

Prognostic accuracy of transcranial magnetic stimulation-induced motor evoked potentials on recovery of upper limb: a systematic review